Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Montefiore Medical Center
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02653196CT.gov A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroepithelial Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Keratinocyte Growth Factor (this asset) | Montefiore Medical Center | Early P1 | C · 39 |
| Tasadenoturev | DNAtrix, Inc. | P2 | B |
| Pembrolizumab | DNAtrix, Inc. | P2 | B |
| Nivestim | St. Jude Children's Research Hospital | P1 | CCC |
| Interleukin-12 | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CCC |
| Sonidegib | St. Jude Children's Research Hospital | P1 | CC |
| Ribociclib | St. Jude Children's Research Hospital | P1 | CC |
| Trametinib | St. Jude Children's Research Hospital | P1 | CC |
| G 207 | M.D. Anderson Cancer Center | P1 | CC |
+7 more in the Neuroepithelial Neoplasm cohort
Other indications for Keratinocyte Growth Factor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Hematopoietic Stem Cell Transplant | — | Early P1 | C · 38 |
| Neoplasm | — | Early P1 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Keratinocyte Growth Factor in Neuroepithelial Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/keratinocyte-growth-factor-neuroepithelial-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →